AR125296A1 - Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 - Google Patents
Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1Info
- Publication number
- AR125296A1 AR125296A1 ARP220100836A ARP220100836A AR125296A1 AR 125296 A1 AR125296 A1 AR 125296A1 AR P220100836 A ARP220100836 A AR P220100836A AR P220100836 A ARP220100836 A AR P220100836A AR 125296 A1 AR125296 A1 AR 125296A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- methods
- binding fragment
- subcutaneous administration
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000007920 subcutaneous administration Methods 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 4
- 229940124060 PD-1 antagonist Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 229960002621 pembrolizumab Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a métodos para tratar el cáncer en un paciente, que comprenden administrar por vía subcutánea un antagonista de PD-1, p. ej., un anticuerpo antiPD-1 o fragmento de unión a antígeno del mismo (p. ej., en cantidades específicas al paciente. En algunas realizaciones, la administración se produce aproximadamente cada tres semanas. En algunas realizaciones, la cantidad de anticuerpo anti-PD-1 o fragmento de unión al antígeno del mismo es de aproximadamente 280 mg a aproximadamente 450 mg. En determinadas realizaciones, el antagonista de PD-1 es pembrolizumab o un fragmento de unión al antígeno del mismo. También se proporcionan composiciones y kits formulados para administración subcutánea que comprenden una dosis de un anticuerpo anti-PD-1, o fragmento de unión al antígeno del mismo, y sus usos para tratar el cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172299P | 2021-04-08 | 2021-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125296A1 true AR125296A1 (es) | 2023-07-05 |
Family
ID=83546458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100836A AR125296A1 (es) | 2021-04-08 | 2022-04-04 | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4320163A1 (es) |
| JP (1) | JP2024513247A (es) |
| KR (1) | KR20230170029A (es) |
| CN (1) | CN117279952A (es) |
| AR (1) | AR125296A1 (es) |
| AU (1) | AU2022254960A1 (es) |
| BR (1) | BR112023020867A2 (es) |
| CA (1) | CA3214617A1 (es) |
| CO (1) | CO2023013273A2 (es) |
| CR (1) | CR20230473A (es) |
| DO (1) | DOP2023000216A (es) |
| EC (1) | ECSP23076276A (es) |
| IL (1) | IL307430A (es) |
| PE (1) | PE20240051A1 (es) |
| TW (1) | TW202305009A (es) |
| WO (1) | WO2022216580A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111032085A (zh) * | 2017-06-05 | 2020-04-17 | 昆士兰医学研究所理事会 | 用于癌症治疗或预防的免疫检查点分子拮抗剂和rank-l（nf-kb配体）拮抗剂的组合或其双特异性结合分子及其用途 |
| CA3090996A1 (en) * | 2018-02-13 | 2019-08-22 | Merck Sharp & Dohme Corp. | Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies |
| US20210380694A1 (en) * | 2018-11-07 | 2021-12-09 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
-
2022
- 2022-04-01 TW TW111112795A patent/TW202305009A/zh unknown
- 2022-04-04 AU AU2022254960A patent/AU2022254960A1/en active Pending
- 2022-04-04 EP EP22785209.2A patent/EP4320163A1/en active Pending
- 2022-04-04 BR BR112023020867A patent/BR112023020867A2/pt unknown
- 2022-04-04 WO PCT/US2022/023250 patent/WO2022216580A1/en active Application Filing
- 2022-04-04 IL IL307430A patent/IL307430A/en unknown
- 2022-04-04 KR KR1020237038583A patent/KR20230170029A/ko active Search and Examination
- 2022-04-04 CA CA3214617A patent/CA3214617A1/en active Pending
- 2022-04-04 CR CR20230473A patent/CR20230473A/es unknown
- 2022-04-04 JP JP2023561333A patent/JP2024513247A/ja active Pending
- 2022-04-04 PE PE2023002821A patent/PE20240051A1/es unknown
- 2022-04-04 AR ARP220100836A patent/AR125296A1/es unknown
- 2022-04-04 CN CN202280033638.8A patent/CN117279952A/zh active Pending
-
2023
- 2023-10-05 CO CONC2023/0013273A patent/CO2023013273A2/es unknown
- 2023-10-05 DO DO2023000216A patent/DOP2023000216A/es unknown
- 2023-10-06 EC ECSENADI202376276A patent/ECSP23076276A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117279952A (zh) | 2023-12-22 |
| JP2024513247A (ja) | 2024-03-22 |
| AU2022254960A9 (en) | 2023-11-30 |
| ECSP23076276A (es) | 2023-11-30 |
| EP4320163A1 (en) | 2024-02-14 |
| DOP2023000216A (es) | 2023-11-30 |
| CA3214617A1 (en) | 2022-10-13 |
| AU2022254960A1 (en) | 2023-11-23 |
| KR20230170029A (ko) | 2023-12-18 |
| IL307430A (en) | 2023-12-01 |
| TW202305009A (zh) | 2023-02-01 |
| CO2023013273A2 (es) | 2023-10-30 |
| WO2022216580A1 (en) | 2022-10-13 |
| CR20230473A (es) | 2023-11-30 |
| PE20240051A1 (es) | 2024-01-09 |
| BR112023020867A2 (pt) | 2023-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
| RU2708374C2 (ru) | Комбинированная терапия для лечения рака | |
| CL2019003142A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso. | |
| CY1120445T1 (el) | Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου | |
| CR10244A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| BR112021002145A2 (pt) | Métodos e composições para inibição da via egf/egfr em combinação com inibidores da quinase de linfoma anaplásico | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| AR115566A1 (es) | Composiciones y procedimientos para el tratamiento del cáncer | |
| CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| Rodriguez-Ruiz et al. | Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control | |
| UY39673A (es) | Pauta posológica de sotorasib | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
| AR125296A1 (es) | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 | |
| CO2021003726A2 (es) | Métodos para reducir el riesgo de diabetes en pacientes que se tratan por enfermedades relacionadas con colesterol alto | |
| CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas | |
| CL2023000553A1 (es) | Uso de un anticuerpo anti-pd-1 y un fármaco antineoplásico citotóxico | |
| CO2021014370A2 (es) | Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen | |
| BR112023016320A2 (pt) | Composição terapêutica e método de combinação de imunoterapia multiplex com vacina contra câncer para tratamento de câncer | |
| BR112023021761A2 (pt) | Regime de dosagem de anti-ifnar1 para injeção subcutânea | |
| MX2022007516A (es) | Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos. | |
| AR122043A1 (es) | Dosificación y administración del anticuerpo anti-ctla-4 activable |